Matinas BioPharma (MTNB)

Matinas BioPharma (MTNB) Stock Price & Analysis


MTNB Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.39 - $1.00
Previous Close$0.41
Average Volume (3M)297.93K
Market Cap
Enterprise Value$64.85M
Total Cash (Recent Filing)$28.76M
Total Debt (Recent Filing)$4.12M
Price to Earnings (P/E)-4.2
May 11, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding216,864,526
10 Day Avg. Volume256,503
30 Day Avg. Volume297,933
Standard Deviation0.30
Financial Highlights & Ratios
Price to Book (P/B)3.18
Price to Sales (P/S)51.33
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-6.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue20.34
Enterprise Value/Gross Profit-4.81
Enterprise Value/Ebitda-2.74
Price Target Upside597.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Matinas BioPharma’s price range in the past 12 months?
Matinas BioPharma lowest stock price was $0.39 and its highest was $1.00 in the past 12 months.
    What is Matinas BioPharma’s market cap?
    Currently, no data Available
    When is Matinas BioPharma’s upcoming earnings report date?
    Matinas BioPharma’s upcoming earnings report date is May 11, 2023 which is in 50 days.
      How were Matinas BioPharma’s earnings last quarter?
      Matinas BioPharma released its earnings results on Mar 15, 2023. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.025 by $0.005.
        Is Matinas BioPharma overvalued?
        According to Wall Street analysts Matinas BioPharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Matinas BioPharma pay dividends?
          Matinas BioPharma does not currently pay dividends.
          What is Matinas BioPharma’s EPS estimate?
          Matinas BioPharma’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Matinas BioPharma have?
          Matinas BioPharma has 217,264,530 shares outstanding.
            What happened to Matinas BioPharma’s price movement after its last earnings report?
            Matinas BioPharma reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.025. Following the earnings report the stock price went up 6.977%.
              Which hedge fund is a major shareholder of Matinas BioPharma?
              Currently, no hedge funds are holding shares in MTNB


              Matinas BioPharma Stock Smart Score

              The Matinas BioPharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
              Learn more about TipRanks Smart Score

              Company Description

              Matinas BioPharma

              Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B; and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded in May 2013 and is headquartered in Bedminster, NJ.


              Forecast EPS vs Actual EPS

              Similar Stocks
              Price & Change
              Oric Pharmaceuticals
              Anixa Biosciences
              Alaunos Therapeutics
              Precision BioSciences
              VBI Vaccines

              Popular Stocks

              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis